| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
Because AI can learn through machine learning and analyze medical images by detecting patterns and anomalies. |
This aligns with the principles of Clinical Decision Support Systems, in which AI augments but does not replace Doctors, but helps improvethe precision, consistency, and speed of medical imaging interpretation |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI tools in radiology are commonly described as assistive technologies that support, but do not replace, radiologists. |
This is like the concept of Clinical Decision Support Systems, where AI will help humans but not replace human |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy encompasses the ability of healthcare professionals and stakeholders to comprehend how AI systems work, their capabilities, limitations, and how to interpret AI-generated outputs responsibly. |
This concept is technology acceptance models and health informatics frameworks, which highlight that understanding technology. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
Because the acceptability of AI is how useful it is and the trust in the AI system, but the color is the outer factor. |
This aligns with the Technology Acceptance Model (TAM), which emphasizes perceived usefulness but the color are irrelevant. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Because the comment from the social can influence the decision of the professionals to to adopt an AI tool |
This is consistent with the Unified Theory of Acceptance and Use of Technology (UTAUT), which identifies social influence as a core determinant of technology adoption behavior, alongside factors like effort expectancy and facilitating conditions. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Fear of losing a job and losing professional autonomy are the main perceived threats. |
Protection Motivation Theory (PMT) posits that individuals’ behavior intentions are shaped by threat appraisal—their perceptions of severity (How bad would it be if AI replaced me?) and vulnerability (How likely is that to happen?). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Medical professionals will accept the AI more if they are useful and easy to use. |
TAM(Technology Acceptance Models) highlights perceived usefulness and ease‑of‑use as key predictors of technology adoption. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The system usage means how the AI system delivers tangible business value and fits into existing clinical processes. |
This aligns with the Technology Acceptance Model (TAM), where the end‐point “actual system use” is driven by perceived usefulness and perceived ease of use. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
The ethicality of AI will impact the acceptability of healthcare professionals because ethics is crucial in the healthcare profession. |
Aligns with the Unified Theory of Acceptance and Use of Technology (UTAUT), which highlights self‑efficacy and performance expectancy as pivotal determinants of technology acceptance in healthcare settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The scoping review argues that future studies must move beyond “ad‑hoc” mono‑method designs (e.g., only interviews or only surveys) to employ mixed‑methods approaches that richly capture both the subjective user experience and the objective realities of workflow integration. |
Aligns with Human‑Centered Design (HCD) principles that emphasize iterative, context‑embedded evaluation of technology within actual user workflows. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
The primary therapeutic aim is to replenish the population of lost dopamine neurons, restoring dopaminergic signaling and improving motor control. |
This approach is in the cell replacement therapy paradigm for neurodegenerative diseases, which seeks to physiologically restore neurotransmitter balance by grafting healthy neurons into affected brain regions. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The authors conducted a 39‑week GLP safety study in athymic nude rats, assessing toxicity, tumorigenicity, and biodistribution at the maximum feasible dose. |
Aligns with the preclinical translational research paradigm, which mandates rigorous in vivo safety and efficacy testing commonly in rodent models. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The GLP-compliant preclinical safety study in immunodeficient athymic nude rats included necropsy and tissue analyses at multiple time points 4, 26, and 39 weeks post‑transplantation. And 39 weeks equal 9 months that's the endpoint. |
This long‑term in vivo assessment aligns with regulatory expectations for toxicology and tumorigenicity testing of cell‑based therapies, where a minimum of 6–9 months of observation is recommended. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
In its abstract, the paper states that it presents preclinical data supporting the first‑in‑human STEM‑PD phase I/IIa clinical trial along with the trial design. |
Phase I evaluates safety and tolerability (often in a small cohort), and Phase IIa begins to explore preliminary signals of efficacy and optimal dosing in a slightly larger group, especially relevant for cell‑based therapies in neurodegenerative diseases. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM‑PD product was produced following a Good Manufacturing Practice (GMP)–compliant differentiation protocol to generate dopamine progenitor cells under fully regulated conditions. |
This manufacturing strategy adheres to the regulatory paradigm for advanced therapy medicinal products (ATMPs), and GMP-compliant conditions is mandatory to guarantee product reproducibility, purity, and safety before clinical application |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The article reports that in a 9‑month GLP‑compliant safety study in athymic nude rats, there are no signs of toxicity and tumorigenicity |
Regulatory frameworks for advanced cell therapies mandate long‑term GLP safety evaluations, including tumorigenicity and biodistribution studies in relevant animal models, to ensure products pose no late‑onset risks before first‑in‑human trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
STEM‑PD cells engrafted successfully and matured into dopaminergic neurons, leading to a full reversal of motor impairments, as evidenced by normalized rotational behavior and improved forelimb use in treated animals. |
This outcome exemplifies the cell replacement therapy paradigm in neurodegenerative disease research, where functional recovery in preclinical models is the critical proof‑of‑concept before advancing to human trials. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
|
This approach reflects standard GMP in vitro quality control practices for ATMPs, ensuring that transplanted cell products uniformly express key developmental markers predictive of in vivo dopaminergic maturation and safety. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
SHH provides a ventralizing signal that specifies floor‑plate identity, while FGF8b emanates from the isthmic organizer to refine cells toward a caudal midbrain fate. |
Applying SHH and FGF8b in vitro faithfully mimics in vivo midbrain patterning cues, ensuring efficient generation of ventral midbrain dopaminergic progenitors for therapeutic use |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
Functional recovery was evidenced by normalized rotational behavior and improved forelimb use in treated animals, demonstrating that the primary efficacy outcome was restoration of motor function. |
This finding exemplifies the cell replacement therapy paradigm in neurodegenerative disease research, where successful in vivo restoration of lost neuronal populations directly translates into behavioral improvements in preclinical models. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|